glp-1 agonist brands list of Receptor Agonists for Diabetes & Weight Loss Market Overview: GLP-1 Agonists and
Description
population received a prescription for one of these medications in 2023
7 , e243604 (2024)
PMID: 26371721 Triplitt C, Chiquette E (2003): Exenatide: from the Gila monster to the pharmacy
[DOI] [PubMed] [Google Scholar] 109.Dicker D
Brain Behav Immun
Both drugs are being developed by Novo Nordisk, likely reflecting a portfolio strategy: CagriSema as the first-to-market injectable combination, and amycretin as a follow-on oral option for patients who prefer pills
